Nischal Ranganath

Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons

Nischal Ranganath, John C. O’Horo, Douglas W. Challener et al. · Clinical Infectious Diseases · 2022 · 80 citations · Full text

Rebound Phenomenon, Additional Covid-19-directed Therapy, Viral Persistence +15

Coronary Artery Calcification, Cardiovascular Events, and Death: A Prospective Cohort Study of Incident Patients on Hemodialysis

Trevor J. Wilkieson, Mozibur Rahman, Azim S. Gangji et al. · Canadian Journal of Kidney Health and Disease · 2015 · 27 citations · Full text

Type I interferon responses are impaired in latently HIV infected cells

Nischal Ranganath, Teslin S. Sandstrom, Saleh Fadel et al. · Retrovirology · 2016 · 21 citations · Full text

Evaluating antimicrobial duration for Gram‐negative bacteremia in patients with neutropenia due to hematologic malignancy or hematopoietic stem cell transplantation

Nischal Ranganath, Zachary A. Yetmar, A. McCandless et al. · Transplant Infectious Disease · 2023 · 15 citations

Vascular Catheter, Immunodeficiencies, Antimicrobial Duration +23

Assessment of Postresuscitation Volume Status by Bioimpedance Analysis in Patients with Sepsis in the Intensive Care Unit: A Pilot Observational Study

Bram Rochwerg, Jason Cheung, Christine Ribic et al. · Canadian Respiratory Journal · 2016 · 14 citations · Full text